EUVIMEDEUVIMED entdecken
Crossref

Lung mucus burden and treatment response assessed by MRI in the post-modulator era

Alexander M Matheson, Evan Prather, Matthew M Willmering, Jaime Mata, Giles Santyr, Felix A Ratjen, Elizabeth L Kramer, Zackary I Cleveland, Jason C Woods

Journal of Cystic Fibrosis · 2026-07 · 25 (4) · 711-717

DOI: 10.1016/j.jcf.2026.05.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2026-07. Verfasst von Alexander M Matheson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pulmonary Imaging Research, Cincinnati Children's Hospital, Cincinnati, OH, United States; Pulmonary Medicine, Cincinnati Children's Hospi…. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Mucus, Cystic Fibrosis, Lung. Die Arbeit nennt 36 Literaturangaben. Gefördert von: NHLBI NIH HHS, Cystic Fibrosis Foundation, Cystic Fibrosis Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Mucus is believed to be central to the progressive nature of cystic fibrosis lung disease. Poor clearance leads to plugging, inflammation, and infection, driving a cycle that eventually results in irreversible lung damage. We hypothesized that patients with higher mucus burden would demonstrate greater improvement in spirometry and ventilation when treated with modulator therapy. METHODS: We retrospectively analyzed data collected in 29 participants prior to and following initiation of elexacaftor/tezacaftor/ivacaftor (ETI) therapy. Participants performed 1H and 129Xe MRI, multiple breath washout tests, and spirometry. Structural abnormalities were quantified using a modified Brody scoring system. 129Xe MRI abnormalities were measured by ventilation defect percent (VDP). RESULTS: Participants with greater mucus burden (the top half, modified Brody score >2.5) showed improved FEV1 (ΔFEV1=10%pred, p=.003), VDP (ΔVDP=-5.6%, p=.004), and lung clearance index (ΔLCI=-1.6, p=.008). Baseline mucus correlated with VDP (ρ=0.48, p = 4e-3), bronchial wall thickening (ρ=0.47, p=.03), and bronchiectasis (ρ=0.80, p = 4e-8). Baseline mucus scores (AUC=0.66) and VDP (AUC=0.75) were associated with lung function improvement (ΔFEV1≥5%pred) following modulator therapy. CONCLUSION: Functional lung improvement following therapy was related to baseline mucus burden, indicating improved mucus clearance potentially drives better lung function in people receiving ETI therapy. MRI lung mucus scores and regional ventilation were both sensitive biomarkers and likely valuable secondary treatment outcomes in future gene therapies or clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Magnetic Resonance ImagingMucusCystic FibrosisLungQuinolonesHumansFemaleRetrospective StudiesMaleAdultSpirometryTreatment OutcomeRespiratory Function TestsChloride Channel Agonists

Stichwörter der Autor:innen

Cystic fibrosisMagnetic resonance imagingModulator therapyMucus

Substanzen

Chloride Channel AgonistsQuinolones

Autor:innen und Institutionen

  • Center for Pulmonary Imaging Research, Cincinnati Children's Hospital, Cincinnati, OH, United States; Pulmonary Medicine, Cincinnati Children's Hospital, Cincinnati, OH, United States.
  • Center for Pulmonary Imaging Research, Cincinnati Children's Hospital, Cincinnati, OH, United States; College of Medicine, The University of Cincinnati, Cincinnati, OH, United States.
  • Center for Pulmonary Imaging Research, Cincinnati Children's Hospital, Cincinnati, OH, United States; Pulmonary Medicine, Cincinnati Children's Hospital, Cincinnati, OH, United States; Department of Pediatrics, The Univ…
  • University of Virginia, Virginia, VA, United States.
  • Department of Radiology, The Hospital for Sick Children, Toronto, ON, Canada; Translational Medicine Program, The Hospital for Sick Children, Toronto, ON, Canada.
  • Translational Medicine Program, The Hospital for Sick Children, Toronto, ON, Canada.

Förderung

  • NHLBI NIH HHS
  • Cystic Fibrosis Foundation
  • Cystic Fibrosis Research Institute
  • National Institutes of Health

Zitieren

APA

Matheson, A. M., Prather, E., Willmering, M. M., Mata, J., Santyr, G., Ratjen, F. A., Kramer, E. L., Cleveland, Z. I., & Woods, J. C. (2026). Lung mucus burden and treatment response assessed by MRI in the post-modulator era. Journal of Cystic Fibrosis, 25(4), 711-717. https://doi.org/10.1016/j.jcf.2026.05.010

Vancouver

Matheson AM, Prather E, Willmering MM, Mata J, Santyr G, Ratjen FA, et al. Lung mucus burden and treatment response assessed by MRI in the post-modulator era. Journal of Cystic Fibrosis. 2026;25(4):711-717. doi:10.1016/j.jcf.2026.05.010

BibTeX
@article{Matheson2026,
  author = {Matheson, Alexander M and Prather, Evan and Willmering, Matthew M and Mata, Jaime and Santyr, Giles and Ratjen, Felix A and Kramer, Elizabeth L and Cleveland, Zackary I and Woods, Jason C},
  title = {Lung mucus burden and treatment response assessed by MRI in the post-modulator era},
  journal = {Journal of Cystic Fibrosis},
  year = {2026},
  volume = {25},
  number = {4},
  pages = {711--717},
  doi = {10.1016/j.jcf.2026.05.010}
}
Kostenlos starten →